Next-Generation Drug Conjugates Oncology Market Global Report 2026

The next-generation drug conjugates oncology market size has grown rapidly in recent years. It will grow from $12.28 billion in 2025 to $13.88 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to the rise of monoclonal antibody therapeutics, increasing global cancer prevalence, improvements in chemotherapy toxicity management, early approvals of targeted oncology biologics, and expansion of oncology clinical trial activity.

The next-generation drug conjugates oncology market size is expected to see rapid growth in the next few years. It will grow to $22.86 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to expansion of precision oncology adoption, increasing investment in biologics and targeted therapy pipelines, expansion of companion diagnostic and biomarker testing, rising demand for targeted cancer therapies in emerging markets, and advancements in next-generation payload engineering and conjugation technologies. Major trends in the forecast period include next-generation linker chemistry optimization improving stability and controlled drug release in antibody-drug conjugates, expansion of novel cytotoxic and immune-modulatory payloads enhancing therapeutic potency against resistant cancer cells, tumor microenvironment-responsive conjugates enabling selective drug activation within cancer tissues, development of multi-specific and dual-targeting drug conjugates addressing tumor heterogeneity and resistance, and increased use of biomarker-driven patient stratification for improved therapeutic precision and clinical outcomes.

The increasing incidence of cancer is expected to drive the expansion of the next-generation drug conjugates oncology market in the future. Cancer incidence refers to the number of newly diagnosed cancer cases within a specific population over a defined time period. The rising incidence of cancer is mainly attributed to an aging population, as advancing age leads to the accumulation of genetic mutations and a reduced ability of the body to repair damaged cells, thereby increasing cancer risk over time. Next-generation drug conjugates in oncology improve cancer treatment by delivering highly potent therapeutic agents directly to tumor cells, increasing treatment precision while minimizing damage to healthy tissues and reducing systemic toxicity. For instance, in January 2026, according to the Centers for Disease Control and Prevention, a US-based government agency, 1,851,238 new cancer cases were reported in 2022, while 613,349 cancer-related deaths occurred in 2023. Therefore, the increasing incidence of cancer is driving the growth of the next-generation drug conjugates oncology market.

Leading companies operating in the next-generation drug conjugates oncology market are focusing on developing innovative therapies such as human epidermal growth factor receptor 3-targeting antibody-drug conjugates (ADCs) to enhance tumor-specific drug delivery, improve treatment efficacy, and reduce systemic toxicity in cancer care. Human epidermal growth factor receptor-targeting antibody-drug conjugates are precision oncology therapies that combine monoclonal antibodies directed against HER3 receptors with potent cytotoxic agents, enabling selective delivery of anti-cancer drugs directly to tumor cells while minimizing damage to healthy tissues compared to conventional chemotherapy. For example, in July 2025, DualityBio Ltd., a China-based biopharmaceutical company, announced that DB-1310 received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced solid tumors with HER3 expression. The therapy is designed using DualityBio’s proprietary antibody-drug conjugate platform and incorporates a HER3-specific monoclonal antibody linked to a highly potent topoisomerase inhibitor payload. It is engineered to improve targeted tumor penetration and intracellular payload delivery while reducing off-target toxicity. The designation supports accelerated development and regulatory review for patients with limited treatment options, highlighting the growing focus on precision-targeted oncology therapeutics and next-generation conjugate technologies in cancer treatment.

In April 2024, Genmab A/S, a Denmark-based biotechnology company, acquired Profound Bio for $1.8 billion. Through this acquisition, Genmab A/S seeks to strengthen its oncology pipeline and expand its next-generation antibody-drug conjugate (ADC) technology capabilities to accelerate the development of targeted cancer therapies. ProfoundBio Inc. is a US-based clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates and advanced oncology technologies for treating solid tumors and other cancers.

Major companies operating in the next-generation drug conjugates oncology market are F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Daiichi Sankyo Company Limited, Lonza Group AG, AbbVie Inc., FUJIFILM Corporation, Lotte Biologics Co Ltd., Ajinomoto Bio-Pharma Services Inc., Hansoh Pharmaceutical Group Company Limited, Piramal Pharma Solutions, Byondis B.V., Mersana Therapeutics, Sutro Biopharma, Alloy Therapeutics Inc., Adagene Inc., Sichuan Kelun-Biotech Biopharmaceutical Co Ltd., Tahoe Therapeutics Inc., Adcendo ApS, HanX Biopharmaceuticals Inc., Sidewinder Therapeutics Inc., Fortitude Biomedicines Inc., Valanx Biotech Pvt Ltd.

North America was the dominant region next-generation drug conjugates oncology market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in next-generation drug conjugates oncology report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation drug conjugates oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation drug conjugates oncology market consists of revenues earned by entities by providing services such as targeted cancer therapy development, antibody-drug conjugate (ADC) research and development, clinical trial and oncology testing services, precision medicine and biomarker analysis, drug conjugate manufacturing, and commercialization services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation drug conjugates oncology market also includes sales of immune-stimulating antibody conjugates, dual-payload drug conjugates, radioligand drug conjugates, aptamer-drug conjugates, and nanoparticle-based drug conjugates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The next-generation drug conjugates oncology market research report is one of a series of new reports that provides next-generation drug conjugates oncology market statistics, including next-generation drug conjugates oncology industry global market size, regional shares, competitors with a next-generation drug conjugates oncology market share, detailed next-generation drug conjugates oncology market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation drug conjugates oncology industry. This next-generation drug conjugates oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.